|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N03AX22
|
|
gptkbp:brand
|
gptkb:Fycompa
|
|
gptkbp:CASNumber
|
380917-97-5
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developer
|
gptkb:Eisai
|
|
gptkbp:eliminationHalfLife
|
105 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C23H15N3O
|
|
gptkbp:hasSMILES
|
C1=CC=C(C=C1)C2=NN(C3=CC=CC=C32)C4=CC=CC=C4C=O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
perampanel
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
AMPA receptor antagonist
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP3A5)
|
|
gptkbp:molecularWeight
|
349.39 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:B3
C
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105757
8067855
9887873
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
falls
aggression
irritability
somnolence
|
|
gptkbp:synonym
|
E2007
2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile
|
|
gptkbp:UNII
|
4Y49E3L79L
|
|
gptkbp:usedFor
|
epilepsy
partial-onset seizures
primary generalized tonic-clonic seizures
|
|
gptkbp:bfsParent
|
gptkb:Fycompa
|
|
gptkbp:bfsLayer
|
7
|